CAR T-cell therapy for hard-to-treat immune thrombocytopenia
Treatments studied
Part of Blood & lymphatic, Immune system & allergy clinical trials.
This trial tests a new type of cell therapy (CAR T cells) that targets and removes specific immune cells causing low platelets. It is for people with immune thrombocytopenia (ITP) that has not improved with standard treatments. The goal is to see if this therapy is safe and can help raise platelet counts.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have had immune thrombocytopenia (ITP) for at least 6 months.
- Your platelet count is very low (below 30,000) on two tests at least a week apart.
- You have tried at least one standard treatment (like steroids or other ITP medications) that did not help enough, or you relapsed after an initial response.
- Your heart, kidneys, liver, and blood counts are within acceptable limits.
- You have not had certain prior treatments or infections (like hepatitis B, C, HIV, or syphilis).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new type of immunotherapy called CAR-T cells that target two proteins (CD19 and BCMA) on immune cells. It is for adults with severe ITP that has not improved with other treatments. The goal is to reset the immune system to stop attacking platelets.
This trial tests a combination of two medications—one that targets specific immune cells (CD20 antibody) and one that blocks a key enzyme in those cells (BTK inhibitor)—for people with ITP or AIHA that hasn't improved after standard treatments. The goal is to see if this combination can help control the disease and reduce symptoms.
This study tests a new type of cell therapy called CAR-T cells that target three proteins (CD19, CD22, BCMA) to treat people with autoimmune diseases that have not responded to standard treatments. The goal is to see if it can reset the immune system and reduce disease activity.
This study tests an investigational drug called CHT105, given as an injection, for people with immune thrombocytopenia (ITP) that has not responded to or has come back after prior treatments. The goal is to see if it can help improve platelet counts and manage the disease.
This early-phase trial tests an investigational cell therapy called PRG-1801 for people with immune thrombocytopenia (ITP) that hasn't responded to or has come back after standard treatments. It aims to see if PRG-1801 can safely help raise platelet counts.
This early-stage trial tests a new type of immune cell therapy (CAR-T) that targets two proteins, CD19 and BCMA, in people with autoimmune blood diseases like ITP, AIHA, or Evans syndrome that have not responded to standard treatments. It aims to reset the immune system and reduce production of harmful antibodies.
Hear when a new Immune Thrombocytopenia (ITP) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.